What's Happening?
Tempest Therapeutics, a clinical-stage biotechnology company based in Brisbane, California, has announced a significant milestone in the development of its dual-targeting CD19/BCMA CAR-T therapy, TPST-2003. The company has successfully delivered the TPST-2003 lentiviral
vector to Cincinnati Children’s Applied Gene and Cell Therapy Center, which is crucial for the manufacturing of this therapy. This development supports Tempest's plans to initiate a potentially registrational study for relapsed/refractory multiple myeloma (rrMM) patients later this year. The announcement follows positive interim data from the ongoing REDEEM-1 Phase 1/2a trial, where all six efficacy evaluable patients achieved a complete response. Tempest aims to present these findings at a scientific meeting later this year.
Why It's Important?
The advancement of TPST-2003 represents a significant step forward in the treatment of relapsed/refractory multiple myeloma, a challenging condition with limited treatment options. The dual-targeting approach of TPST-2003 aims to improve response rates and durability by addressing tumor heterogeneity and antigen escape. This development could potentially offer a new therapeutic option for patients with high-risk cytogenetics and extramedullary disease. The successful manufacturing milestone and upcoming registrational study highlight Tempest's commitment to advancing cancer treatment and could have a substantial impact on the biotechnology industry, particularly in the field of CAR-T therapies.
What's Next?
Tempest plans to initiate the first potentially registrational study for TPST-2003 in the fourth quarter of 2026. The company will continue to collaborate with Cincinnati Children’s Applied Gene and Cell Therapy Center to advance the manufacturing and development of this therapy. Tempest also intends to present the results of the REDEEM-1 trial and updated data from previous studies at a scientific meeting later this year. These steps are crucial for gaining regulatory approval and bringing this innovative treatment to market.
